NextFin News - Hjalmar Nilsonne, chief executive of Neko Health, is making a simple but expensive argument: the way to add years to life is not a single breakthrough scan, but a growing library of scans taken over time. The Swedish preventive-health company, co-founded by Spotify's Daniel Ek, has raised $700 million at a valuation near $7 billion and is opening its first U.S. clinic in Manhattan on Sept. 24, pricing its 60-minute, radiation-free full-body assessment at $499. More than 25,000 New Yorkers are already on the waitlist for that single location, and more than 350,000 people worldwide have signed up or booked. The question investors are really paying for is whether a private, cash-pay scan can do what national health systems have struggled to do for decades — turn early detection into longer, healthier lives at scale.
The Product: A Scan That Only Gets Valuable the Second Time
Neko's pitch is easy to state and harder to prove. The Neko Health Scan uses proprietary sensors plus a blood draw to map millions of data points across skin, blood, metabolic and cardiovascular risk in about an hour, with results delivered in minutes and a physician consultation immediately afterward. The company has built clinics across Sweden and Britain since opening its first site three years ago, and it has secured two U.S. regulatory clearances for internally developed devices: Spectrum-2, cleared as a tissue-saturation oximeter on June 4, 2026, and Derma-2, cleared in May 2026 as an adjunctive telethermographic system. Those clearances apply to the individual devices and their specified uses, not to the full Neko Health Scan as a single FDA-approved screening service — a distinction that matters as the company enters the American market.
The business model turns on repetition. A first scan establishes a baseline; a second scan, ideally a year later, shows movement. That is why the company's strongest evidence is longitudinal rather than cross-sectional. Neko reports outcomes from 1,469 customers who completed a second scan roughly one year after their first at its Stockholm clinics. Across that cohort, the company says blood pressure, cholesterol and blood sugar improved while body weight stayed broadly stable. The improvement was not evenly distributed: customers who began with pre-existing chronic conditions such as diabetes, cardiovascular disease or metabolic syndrome benefited three to five times more than the average member, according to Nilsonne in a recent interview.
The company is careful about what that data can and cannot claim. Neko describes the analysis as not a scientific study and acknowledges it included no control group; customers could have started treatment or changed their behavior between appointments, so the figures do not establish that the scans caused the reported improvements. The analysis covered only customers who returned for a second privately purchased scan, and the company has not published demographic information showing how that group compares with its wider customer base or the general population. That candor is unusual for a company raising hundreds of millions — and it frames the real test ahead.
"The clearest proof is in our members: the vast majority of our members return after their first scan, and when they do, their health markers move in the right direction," Nilsonne said in a statement accompanying the funding announcement.
Retention is the other half of the longitudinal thesis. If members do not come back, the baseline is a one-time souvenir rather than the first chapter of a health record. Neko's claim that the vast majority return is therefore not a vanity metric — it is the operating assumption behind the entire valuation. The company's pricing sits at a point designed to make annual returns plausible: £299 in Britain, roughly $400, and $499 in the United States, a fraction of the cost of executive physicals or whole-body MRI screening packages that run into the thousands. More than 100,000 scans have been delivered to date, out of more than 350,000 people who have signed up or joined a waitlist — a conversion gap that shows real demand and a large pool of interest still to be monetized.
Why the Market Is Paying $7 Billion for Prevention
The $700 million Series C, announced July 15, 2026 and led by Lightspeed Venture Partners with O.G. Venture Partners, values Neko at about $7 billion — roughly four times the $1.8 billion valuation it reached with its $260 million Series B in January 2025. The round attracted an unusual coalition: existing backers General Catalyst, Atomico and Lakestar were joined by Liberty City Ventures, BDT & MSD Partners and Positive Sum, alongside individual investors including Mark Zuckerberg and Priscilla Chan, OpenAI, Tim Ferriss, Maria Sharapova and will.i.am. David Ofer, managing partner of O.G. Venture Partners, will join the board. The capital is earmarked for the U.S. expansion and for continued investment in the research and technology behind the scanning platform.
The timing is not accidental. After a period in which venture capital largely avoided consumer health, money is flowing back into longevity and preventive-care platforms that combine imaging, biomarker testing and AI-enabled analysis to find disease risk before symptoms appear. Investors are betting on a specific behavioral shift: consumers who already track sleep, heart rate and glucose with wearables are now willing to pay out of pocket for diagnostics that used to require a doctor's order. Neko is selling that behavior as a subscription to one's own future — not a scan, but a series of scans.
Nilsonne frames the mission in plainer terms. "This funding is a strong vote of confidence in what we set out to do when we opened our first clinic three years ago," he said, "a completely new healthcare experience designed to keep people healthy, catch problems early and help prevent disease before it even starts."
The Mechanism: Longitudinal Data Beats a One-Time Snapshot
The central analytical question is whether Neko's model actually changes health outcomes, or merely changes how often healthy, anxious people get checked. A single scan can find a mole, flag an irregular heartbeat or detect pre-diabetes. But discovery alone does not extend life — action does. The longitudinal design is Neko's answer to that gap. By re-scanning the same person annually, the company converts a static finding into a trajectory. A borderline cholesterol reading becomes meaningful when the second scan shows it rising despite lifestyle advice; a stable mole over three years is reassuring in a way a single image cannot be.
This is where the cohort data carries weight, even with its acknowledged limitations. The 1,469-person repeat-scanner group is not a randomized control trial, and the company does not claim it is. But the direction of the data is consistent with what preventive medicine would predict: people who learn they are pre-diabetic or hypertensive, then re-test a year later, tend to show improvement — because the measurement itself triggers behavior change, medication adherence, or clinical follow-up that would not have happened otherwise. The three-to-five-times larger benefit among members who started with chronic conditions is the clearest signal that the service is finding people at the margin where intervention still works.
The transmission mechanism, then, is not the scanner. It is the feedback loop: measure, show, consult, re-measure. The AI is the layer that makes the feedback legible — turning millions of sensor and blood data points into a report a person can act on in minutes rather than weeks. That is the structural claim: AI plus proprietary hardware plus a repeat-visit business model creates a prevention engine that improves with each additional data point on each individual. A one-time scan is a product. A longitudinal record is an asset that compounds.
Cyclical Hype Meets a Structural Shift
It is important to separate the two forces at work here, because conflating them produces the wrong investment conclusion.
The cyclical force is the wellness-tech funding boom itself. Celebrity investors, a $7 billion private valuation, and a 25,000-person waitlist in one neighborhood are the markers of a hot market. Waitlists are not revenue, and they can evaporate when the novelty fades or when the first wave of early adopters has been served. The conversion gap — more than 350,000 signups against just over 100,000 scans delivered — shows both real demand and a large distance between interest and paid action. If the U.S. launch disappoints on retention, or if the outcomes cohort fails to replicate in a larger, more diverse population, the valuation multiple will compress quickly. This leg of the story is mean-reverting: hype recedes, and companies are judged on unit economics.
The structural force is different, and it is the reason the sector is attracting serious capital despite the hype cycle. Healthcare systems in the U.S., Britain and Sweden are overwhelmingly reactive: they intervene after symptoms appear, when treatment is expensive and outcomes are worse. The cost pressure is not going away — it is accelerating with aging populations. A prevention model that can shift diagnosis earlier, at a price consumers pay directly, addresses a durable structural problem. The evidence that this shift is real, not faddish, is in the regulatory path: Neko has moved its devices through the FDA's 510(k) pathway, and the company's repeat-scan outcomes data, while not peer-reviewed, is the kind of evidence that payers and employers will eventually demand. The structural claim rests on three pillars: a permanent change in consumer willingness to pay for prevention, technology that gets more accurate with more longitudinal data, and a regulatory footprint that makes U.S. scaling possible. None of those self-corrects back to the old model.
The correct read is that both forces are present. The cyclical leg says the private valuation could fall if the U.S. launch stumbles. The structural leg says that even a lower valuation would not mean prevention is a dead end — it would mean this particular company overpaid for its entry ticket. Investors should argue the two legs separately rather than let a bad launch quarter talk them out of a real regime shift, or let a hot launch talk them into ignoring unit economics.
The Counter-Thesis: Early Detection Has a Long History of Overpromising
The strongest argument against Neko is not that the technology fails, but that the epidemiology of screening is littered with good intentions. Whole-body CT and MRI screening have existed for years, and mainstream medicine has remained skeptical because early detection carries real harms: false positives, incidental findings, unnecessary biopsies, anxiety, and overdiagnosis of conditions that would never have caused symptoms. A cash-pay model intensifies the concern, because the company's revenue depends on people coming back and finding things to address. The incentive to flag borderline results is embedded in the business.
There is also the selection-bias problem. The 1,469-person outcomes cohort consists of people healthy and wealthy enough to pay for a scan twice, in Stockholm. That is not the population that carries the highest burden of cardiovascular or metabolic disease. Without a matched control group — similar people who did not scan — the improvement in blood pressure and cholesterol cannot be cleanly attributed to Neko rather than to regression to the mean, seasonal effects, or concurrent medical care. The company's own leadership has acknowledged it lacks conclusive causal evidence.
The answer to the counter-thesis is not to dismiss it but to name what would resolve it. Neko's model does not need to prove it beats randomized trials on day one; it needs to prove that its longitudinal data predicts hard outcomes better than standard annual checkups at a similar cost. That is a testable claim, and the company has the data infrastructure to run it. The physician consultation attached to every scan is the bridge from detection to action — the piece that pure imaging competitors such as Prenuvo lack. If Neko can show that members who act on scan findings have fewer hospitalizations, new diagnoses at earlier stages, or lower medication burden over three to five years, the skepticism becomes a moat: the data asset compounds while competitors are still arguing about whether screening works at all.
What Comes Next: The U.S. Launch as the First Real Test
The Manhattan clinic opening Sept. 24 at 300 Lafayette Street is the first controlled experiment in the company's history. Europe provided proof of concept; the United States provides proof of scale, at prices and in a population that have never been tested. Planned locations in Miami, Washington, D.C., and San Francisco suggest the company is betting on affluent, health-conscious urban markets first — the same demographic most likely to convert from waitlist to paid scan, and the same demographic most likely to return annually.
Short term, the signals to watch are conversion and retention: how many of the 25,000 New York waitlist members book and show up, and how many return for a second scan within 12 to 15 months. Medium term, the question is whether the outcomes cohort replicates in the U.S. population and whether the company can move from cash-pay consumers toward employer or insurer reimbursement, which is where the real scale sits. Long term, the structural bet resolves on whether longitudinal AI-driven prevention becomes a standard layer of care — in which case Neko's early data library becomes a defensible asset — or whether it remains a premium consumer service with a ceiling.
The falsifying signal is specific: if an independent, peer-reviewed study or registry of Neko members shows no difference in hard clinical outcomes versus matched controls over two to three years, or if U.S. re-scan retention falls below 50 percent at the first anniversary, the structural thesis is wrong and the $7 billion valuation is a bubble. Conversely, if retention holds and outcomes improve in a larger, more diverse cohort, the company has done something rare in digital health: it has turned a consumer product into a longitudinal data asset that gets more valuable the longer it runs.
The bottom line: Neko Health is not selling a scan. It is selling the second scan — the moment a baseline becomes a trend, and a trend becomes a reason to act. That is a harder business to build than an imaging clinic, but it is also the only version of the story that justifies $7 billion. The Manhattan launch will show, within a year, which business the company actually has.
Explore more exclusive insights at nextfin.ai.
